The prognosis of latent tuberculosis: can disease be predicted?

Trends in Molecular Medicine

Volumn 13, Issue 5, 2007, Pages 175-182

  Andersen, Peter ^a   Doherty, T Mark ^a   Pai, Madhukar ^b   Weldingh, Karin ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; GAMMA INTERFERON; MYCOBACTERIUM TUBERCULOSIS ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION ANALYSIS; CYTOKINE RELEASE; DIAGNOSTIC TEST; DISEASE COURSE; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LATENT PERIOD; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT IDENTIFICATION; PREDICTION; PROGNOSIS; T LYMPHOCYTE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DISEASE PROGRESSION; HUMANS; INTERFERON TYPE II; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; T-LYMPHOCYTES; TUBERCULIN TEST; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34247555886     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.03.004     Document Type: Article

References (63)

1. WHO Report (2005) Global tuberculosis control - surveillance, planning, financing. World Health Organization (WHO/HTM/TB/2005.349)
2. Pai M., et al. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4 (2004) 761-776
3. Lalvani A., et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357 (2001) 2017-2021
4. Brock I., et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am. J. Respir. Crit. Care Med. 170 (2004) 65-69
5. Mazurek G.H., et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm. Rep. 54 (2005) 49-55
6. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat. Rev. Immunol. 1 (2001) 20-30
7. Russell D.G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2 (2001) 569-577
8. Sherman D.R., et al. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7534-7539
9. Andersen P., et al. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect. Immun. 59 (1991) 1558-1563
10. Leyten E.M., et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 8 (2006) 2052-2060
11. Demissie A., et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin. Vaccine. Immunol. 13 (2006) 179-186
12. Wilkins E.G., and Ivanyi J. Potential value of serology for diagnosis of extrapulmonary tuberculosis. Lancet 336 (1990) 641-644
13. Weldingh K., et al. Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens. J. Clin. Microbiol. 43 (2005) 57-65
14. Wallis R.S., et al. Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. J. Infect. Dis. 178 (1998) 1115-1121
15. Choudhry V., and Saxena R.K. Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 21 (2002) 1-5
16. Edwards, P.Q. and Edwads, L.B. (1960) Story of the tuberculin test from an epidemiologic viewpoint. Am. Rev. Respir. Dis. 81(1)Pt 2, 1-47
17. Judson F.N., and Feldman R.A. Mycobacterial skin tests in humans 12 years after infection with Mycobacterium marinum. Am. Rev. Respir. Dis. 109 (1974) 544-547
18. Mori T., et al. Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am. J. Respir. Crit. Care Med. 170 (2004) 59-64
19. Kang Y.A., et al. Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. J. Am. Med. Assoc. 293 (2005) 2756-2761
20. Hill P.C., et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 117 (2006) 1542-1548
21. Jasmer R.M., et al. Clinical practice. Latent tuberculosis infection. N. Engl. J. Med. 347 (2002) 1860-1866
22. Berkel G.M., et al. Tuberculin skin test: estimation of positive and negative predictive values from routine data. Int. J. Tuberc. Lung Dis. 9 (2005) 310-316
23. Jeyakumar D. Tuberculin reactivity and subsequent development of tuberculosis in a cohort of student nurses. Med. J. Malaysia 54 (1999) 492-495
24. Leung C.C., et al. Risk of active tuberculosis among schoolchildren in Hong Kong. Arch. Pediatr. Adolesc. Med. 160 (2006) 247-251
25. Harboe M., et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 64 (1996) 16-22
26. Behr M.A., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 (1999) 1520-1523
27. Andersen P., et al. Specific immune-based diagnosis of tuberculosis. Lancet 356 (2000) 1099-1104
28. Andersen P., et al. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol. 154 (1995) 3359-3372
29. Shi L., et al. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung. Infect. Immun. 72 (2004) 2420-2424
30. Brodin P., et al. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect. Immun. 74 (2006) 88-98
31. Pai M., et al. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev. Mol. Diagn. 6 (2006) 413-422
32. Chapman A.L., et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16 (2002) 2285-2293
33. Taggart E.W., et al. Evaluation of an in vitro assay for γ interferon production in response to Mycobacterium tuberculosis infections. Clin. Diagn. Lab. Immunol. 11 (2004) 1089-1093
34. Ferrara G., et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367 (2006) 1328-1334
35. Diel R., et al. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir. Res. 7 (2006) 77
36. Shams H., et al. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 172 (2005) 1161-1168
37. Ewer K., et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361 (2003) 1168-1173
38. Pai M., et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon γ assay with tuberculin skin testing. J. Am. Med. Assoc. 293 (2005) 2746-2755
39. Arend S.M., et al. Comparison of two interferon-γ assays and tuberculin skin test for tracing TB contacts. Am. J. Respir. Crit. Care Med. 175 (2006) 618-627
40. Diel R., et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur. Respir. J. 28 (2006) 35-44
41. Harada N., et al. Basic characteristics of a novel diagnostic method (QuantiFERON TB-2G) for latent tubercolosis infection with the use of Mycobacterium tubercolosis-specific antigens, ESAT-6 and CFP-10. Kekkaku 79 (2004) 725-735
42. Harada N., et al. Screening for tuberculosis infection using whole-blood interferon-γ and Mantoux testing among Japanese healthcare workers. Infect. Control Hosp. Epidemiol. 27 (2006) 442-448
43. Winslow G.M., et al. Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse. J. Immunol. 170 (2003) 2046-2052
44. Dietrich J., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174 (2005) 6332-6339
45. Buddle B.M., et al. Differentiation between Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle by using recombinant mycobacterial antigens. Clin. Diagn. Lab. Immunol. 6 (1999) 1-5
46. Vordermeier H.M., et al. Correlation of ESAT-6-specific γ interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. 70 (2002) 3026-3032
47. Skinner M.A., et al. A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis. Infect. Immun. 71 (2003) 4901-4907
48. Lyashchenko K., et al. Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis. Infect. Immun. 72 (2004) 2462-2467
49. Langermans J.A., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 (2005) 2740-2750
50. Ravn P., et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179 (1999) 637-645
51. Doherty T.M., et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40 (2002) 704-706
52. Demissie A., et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4δ2. J. Immunol. 172 (2004) 6938-6943
53. Hill P.C., et al. Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model. Clin. Infect. Dis. 40 (2005) 273-278
54. Pai M., et al. Serial testing of health care workers for tuberculosis using interferon-γ assay. Am. J. Respir. Crit. Care Med. 174 (2006) 349-355
55. Corbett E.L., et al. Tuberculosis infection in African nursing students: tuberculin skin test compared to ELISPOT conversion rates. Int. J. Tuberc. Lung Dis. 10 (2006) 231
56. Whalen C.C., et al. Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. Am. J. Trop. Med. Hyg. 75 (2006) 55-61
57. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am. J. Respir. Crit. Care Med. 159 (1999) 15-21
58. Pathan A.A., et al. Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J. Immunol. 167 (2001) 5217-5225
59. Carrara S., et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin. Infect. Dis. 38 (2004) 754-756
60. Aiken A.M., et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect. Dis. 6 (2006) 66
61. Dheda K., et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 19 (2005) 2038-2041
62. Doherty T.M., and Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin. Microbiol. Rev. 18 (2005) 687-702
63. Soysal A., et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366 (2005) 1443-1451